Compare Ascendis Pharma A/S (ASND) vs Gartner Inc (IT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Gartner Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Gartner Inc trades at $133.64 (market cap $8.92B). The key difference: Ascendis Pharma A/S is the larger of the two by market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Gartner Inc nearer its low. Which is the better fit depends on your goals.
| ASND | IT | |
|---|---|---|
Market Cap | $17.74B | $8.92B |
Sector | Health | Technology |
52-Week High | $277.18 | $374.40 |
52-Week Low | $163.32 | $125.68 |
Enterprise Value | $18.11B | $10.51B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Gartner (IT) trades at $133.24, up 0.41% today, with a bearish technical signal but strong recent earnings beats. The company shows robust profitability with a 68.99% gross margin and 11.44% net margin, though 2025 net income declined to $729M from $1.3B in 2024. Analyst consensus is mixed with a $157.60 price target, while news highlights ongoing investigations and industry events.
Outlook is cautious due to technical bearishness and net cash outflows, but valuation appears reasonable with a P/E of 13.17. Risks include competitive pressures and the recent legal investigation. Upside potential exists if earnings momentum continues and sentiment improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Gartner Inc
Based in Stamford, Conn., Gartner provides independent research and analysis on information technology and other related technology industries. Its research is delivered to clients' desktops in the form of reports, briefings, and updates. Typical clients are chief information officers and other business executives who help plan companies' IT budgets. Gartner also provides consulting services and hosted nearly 80 IT conferences across the globe in 2007.
Read more on IT →
